Congress bans U.S. drug and prosthetics exports to Russia over Ukraine
H.R. 4762 — Medical Supply Sanctions Act of 2025 · Filed by Morgan Luttrell (R-TX) · Introduced Jul 25, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the export of FDA-approved drugs and prosthetics (including all components) to Russia, effective immediately. The ban remains in place until the Secretary of State certifies that Russia has ended military operations in Ukraine and withdrawn its forces—making it a conditional sanctions measure tied to Russian military conduct.
Why we flagged it
The bill is a straightforward export control tied to Russian military conduct in Ukraine. It uses trade restrictions as a foreign-policy tool, not as a regulatory or domestic-policy mechanism. The operative mechanism is transparent: prohibit exports until a condition (Russian withdrawal) is met.
What the text implies
- The definition of 'drug' is tied to FDA approval under specific sections of the FDCA and PHS Act, which may exclude some medications (e.g., compounded drugs, investigational drugs, or those approved under emergency pathways) and create ambiguity about what counts as an export-prohibited 'drug.'
- The sunset clause depends on a single certification by the Secretary of State—a political actor—creating potential for the ban to persist or lift based on diplomatic judgment rather than objective military facts, and no requirement for congressional approval of the certification.
The full analysis lists 4 implications of this text.
Who it affects
U.S. pharmaceutical and prosthetics manufacturers lose export revenue and market access (a cost to their business and workers), while U.S.